The importance of patient participation in measuring rheumatoid arthritis flares

Annals of the Rheumatic Diseases

Volumn 71, Issue 7, 2012, Pages 1107-1109

  Bingham III, Clifton O ^a   Alten, Rieke ^b   De Wit, Maarten P ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

CLINICAL PRACTICE; COPING BEHAVIOR; DISABILITY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; MEDICAL DECISION MAKING; PATIENT PARTICIPATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PHYSICIAN'S ROLE;

EID: 84862511432     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200870     Document Type: Editorial

References (32)

1. Bingham CO, Pohl C, Alten R, et al. 'Flare' and disease worsening in rheumatoid arthritis: time for a definition. Int J Adv Rheumatol 2009;7:85-91.
2. Bingham CO III, Pohl C, Woodworth TG, et al. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009;36:2335-41.
3. Alten R, Pohl C, Choy EH, et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol 2011;38:1745-50.
4. Bingham CO III, Alten R, Bartlett SJ, et al. Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. J Rheumatol 2011;38:1751-8.
5. Hewlett S, Sanderson T, May J, et al. 'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count - an international patient perspective on flare where medical help is sought. Rheumatology (Oxford). 2012 Jan;51:69-76.
6. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
7. de Wit MP, Smolen JS, Gossec L, et al. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 2011;70:891-5.
8. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
9. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
10. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
11. Den Broeder AA, Creemers MC, van Gestel AM, et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford) 2002;41:638-42. (Pubitemid 34618881)
12. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-8. (Pubitemid 47309743)
13. Leeb BF, Sautner J, Leeb BA, et al. Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes. Scand J Rheumatol 2006;35:441-6. (Pubitemid 47215711)
14. Barton JL, Imboden J, Graf J, et al. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:857-64.
15. Khan NA, Spencer HJ, Abda E, et al. Determinants of discordance in patient's and physician's rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2 Nov 2011. doi:10.1002/acr.20685.
16. de Wit MP, Berlo SE, Aanerud GJ, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis 2011;70:722-6.
17. Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 2010;10:22.
18. European Medicines Agency (EMEA). Reflection Paper on the Regulatory Guidance for the Use of Health-related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products, 2005. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003637.pdf (accessed 11 Oct 2011).
19. FDA. Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. http://wwwfdagov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282pdf (accessed 11 Oct 2011).
20. Critical Path Institute (cPATH). Patient Reported Outcomes (PRO) Consortium. http://wwwc-pathorg/PROcfm (accessed 11 Oct 2011).
21. German Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlickeit im Gesundheitswesen). Biotechnologisch hergestellte Arzneimittel in der Zweitlinientherapie bei der rheumatoiden Arthritis. https://www.iqwig.de/download/A10-01-Berichtsplan- Biologika-Zweitlinientherapie-bei-rheumatoider-Arthritis.pdf (accessed 11 Oct 2011).
22. Kirwan JR, Newman S, Tugwell PS, et al. Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of life impact measures at OMERACT 9. J Rheumatol 2009;36:2071-6.
23. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at OMERACT 7. J Rheumatol 2005;32:2250-6. (Pubitemid 41587877)
24. Kirwan JR, Ahlmén M, de Wit M, et al. Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. J Rheumatol 2005;32:2246-9.
25. Kirwan J, Heiberg T, Hewlett S, et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol 2003;30:868-72. (Pubitemid 36402790)
26. Gossec L, Dougados M, Rincheval N, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680-5.
27. Kirwan JR, Fries JF, Hewlett SE, et al. Patient perspective workshop: moving towards OMERACT guidelines for choosing or developing instruments to measure patient-reported outcomes. J Rheumatol 2011;38:1711-15.
28. Kirwan JR, Tugwell PS. Overview of the patient perspective at OMERACT 10-conceptualizing methods for developing patient-reported outcomes. J Rheumatol 2011;38:1699-701.
29. Sanderson T, Morris M, Calnan M, et al. Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken) 2010;62:647-56.
30. Gossec L, Paternotte S, Aanerud GJ, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 2011;70:935-42.
31. Berthelot JM, De Bandt M, Morel J, et al . A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: The 'FLARE' instrument. Ann Rheum Dis 2012.
32. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004;59:94-9. (Pubitemid 38223477)